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Lack of Enhanced Spinal Regeneration
in Nogo-Deficient Mice
that are thought to reflect a failed attempt at elongation
(Ramon y Cajal, 1928; Schwab and Bartholdi, 1996).
Axonal regeneration following spinal cord injury is be-
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lieved to be prevented by multiple factors, including a1Department of Biological Sciences
reduced propensity of adult CNS axons for axonalHoward Hughes Medical Institute
growth (Fawcett, 1992; Goldberg et al., 2002), the ab-Stanford University
sence of some positive factors in the environment ofStanford, California 94305
the injured adult CNS (Jakeman and Reier, 1991), and2 Department of Neurology
the presence of inhibitory factors that actively blockYale University School of Medicine
axonal regrowth (Schwab and Bartholdi, 1996). The de-New Haven, Connecticut 06520
velopment of therapies for axonal regeneration will re-3 Reeve-Irvine Research Center
quire overcoming these inhibitory influences. There isGillespie Neuroscience Research Facility
evidence for multiple extracellular inhibitors contribut-College of Medicine
ing to inhibition block. Factors associated with the lesionUniversity of California, Irvine
site and scar tissue, including proteoglycans (Fitch andIrvine, California 92697
Silver, 1997) and possibly members of the semaphorin
family (Pasterkamp et al., 1999), are believed to contrib-
ute significantly (Bradbury et al., 2002). Factors associ-
Summary ated with the myelin sheath of axons, made by oligoden-
drocytes, have also been proposed to be an important
The failure of regeneration of severed axons in the source of inhibition (Schwab and Caroni, 1988). The first
adult mammalian central nervous system is thought characterized inhibitor from myelin was myelin-associ-
to be due partly to the presence of endogenous inhibi- ated glycoprotein (MAG), a potent inhibitor of axon
tors of axon regeneration. The nogo gene encodes growth in vitro (McKerracher et al., 1994; Mukhopadhyay
three proteins (Nogo-A, -B, and -C) that have been et al., 1994). In vivo, however, loss of MAG function fails
proposed to contribute to this inhibition. To determine to promote extensive regeneration (Bartsch et al., 1995;
whether deletion of nogo enhances regenerative abil- Li et al., 1996), prompting the search for additional my-
ity, we generated two lines of mutant mice, one lacking elin-associated inhibitors.
Nogo-A and -B but not -C (Nogo-A/B mutant), and one The second inhibitor from myelin to be characterized
deficient in all three isoforms (Nogo-A/B/C mutant). molecularly was Nogo-A (Spillmann et al., 1998; Chen
Although Nogo-A/B-deficient myelin has reduced in- et al., 2000; GrandPre´ et al., 2000; Prinjha et al., 2000).
hibitory activity in a neurite outgrowth assay in vitro, Much interest has focused on this protein and its possi-
tracing of corticospinal tract fibers after dorsal hemi- ble involvement in inhibition of axonal regeneration be-
section of the spinal cord did not reveal an obvious cause of evidence that in vivo delivery of antibodies
increase in regeneration or sprouting of these fibers against Nogo can help stimulate regeneration of axons
in either mouse line, suggesting that elimination of and compensatory sprouting and enhance functional
Nogo alone is not sufficient to induce extensive axon recovery in animal models of spinal cord injury (Schnell
regeneration. and Schwab, 1990; Bregman et al., 1995; Thallmair et
al., 1998; Brosamle et al., 2000). Although provocative,
these studies left a number of questions unanswered,Introduction
especially regarding the cellular and molecular basis of
the growth inhibition.During development, neuronal axons, tipped by growth
First, it is not obvious how Nogo-A could operatecones, extend from their cell bodies of origin to reach
as an extracellular inhibitor in the uninjured nervoustheir synaptic targets. In the adult, traumatic injury can
system. It has two transmembrane domains but no sig-lead to the severing of axons and thus to loss of func-
nal sequence, and it possesses an endoplasmic reticu-tional connections. The distal portion of the axon, dis-
lum (ER) retention sequence (Chen et al., 2000; GrandPre´connected from the neuronal cell body, undergoes de-
et al., 2000; Prinjha et al., 2000). Indeed, most Nogo
generation (“Wallerian degeneration”) over several weeks.
protein appears localized to an intracellular compart-
The proximal portion, in contrast, rapidly initiates a re-
ment in cells (perhaps the ER) (GrandPre´ et al., 2000).
generative response: the cut end of the axon reseals This localization seems at odds with a possible involve-
itself, re-forms a growth cone like those on embryonic ment in inhibition of regeneration. The protein could be
axons, and attempts to re-extend (Ramon y Cajal, 1928). accessible to axons if it is released from dying oligoden-
In the mammalian peripheral nervous system (PNS), this drocytes following injury, but this would only explain
regeneration can often be successful. In the mammalian growth inhibition in circumscribed regions where those
central nervous system (CNS, the brain and spinal cord), cells are dying. It could contribute to growth inhibition
however, the attempted regeneration fails, and the cut in undamaged areas only if some of the protein is present
axon tips assume a club-like morphology (“end bulbs”) on the myelin surface, a possibility for which some evi-
dence has been obtained (GrandPre´ et al., 2000; Huber
et al., 2002).*Correspondence: marctl@stanford.edu
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Figure 1. Generation of Nogo-A/B Mutant
and Nogo-A/B/C Mutant Mice
(A) Structure of the murine nogo gene in rela-
tion to the three isoforms. Top: three Nogo
isoforms. The two black bars in the C-terminal
common region represent the two transmem-
brane domains that are separated by a 66
amino acid loop. Bottom: nogo genomic
structure. The black bars indicate exons.
Arrows indicate promoter regions. Nogo-A
and -B share a promoter while Nogo-C has
an alternative promoter.
(B–E) Targeting the N terminus of Nogo to
generate the Nogo-A/B mutant.
(B) Targeting strategy for the Nogo-A/B mu-
tant. WT, wild-type; IRES, internal ribosomal
entry site; GFP, green fluorescent protein
gene; LacZ, -galatosidase gene; Hprt, hypo-
xanthine phosphoribosyltransferase gene
under the control of the PGK (phosphoglycer-
ate kinase) gene promoter; TK, Herpes Sim-
plex Virus thymidine kinase gene. loxP and frt
sites (recognized by Cre and Flp site-specific
recombinases, respectively) are introduced
into the targeted allele to facilitate further ma-
nipulation of the targeted locus.
(C) Southern analysis of ES cell DNA to iden-
tify the targeted clones. , wild-type allele;
m, mutant allele.
(D) Northern analysis of total brain RNA from
wild-type and homozygous Nogo-A/B mutant
mice using a probe corresponding to the cod-
ing portion of the C-terminal common region
of nogo cDNA. nogo-A, -B, and -C transcripts
run at about 4.7 kb, 2.6 kb, and 1.7 kb, respec-
tively.
(E) Western blots on total adult brain extracts
using anti-Nogo antibodies (top, anti-Nogo-A;
bottom, anti-Nogo N terminus, to detect
Nogo-B).
(F–J) Targeting the C terminus of Nogo to
generate the Nogo-A/B/C mutant.
(F) Targeting strategy for the Nogo-A/B/C mu-
tant. Neo, neomycin resistance gene under
the control of the PGK promoter. TM, trans-
membrane domain.
(G) Southern analysis of ES cell DNA to iden-
tify the targeted clones.
(H) Northern analysis of total brain RNA from
wild-type, heterozygous, and homozygous
Nogo-A/B/C mutant mice (derived from the
escaper) using the same probe as in (D). Note
the presence of a lower level of a shortened
Nogo-C transcript in the homozygous mutant (see text).
(I) RT-PCT analysis on nogo-C transcripts in wild-type and Nogo-A/B/C mutant mice using a primer set that specifically amplifies Nogo-C
transcripts.
(J) Western blot analysis on total brain extract of wild-type and homozygous mutant adult mice using the anti-Nogo-A antibody. Arrow indicates
the position of Nogo-A.
Second, there is controversy regarding the portion(s) also present on the cell surface (Chen et al., 2000). Add-
ing to the paradox, the in vivo experiments that sug-of the Nogo molecule that mediates axonal inhibition.
There are three major isoforms (A, B, and C) of Nogo gested a role of Nogo in regeneration (Schnell and
Schwab, 1990; Bregman et al., 1995; Thallmair et al.,arising by alternative splicing and promoter usage (Fig-
ure 1A; Chen et al., 2000; GrandPre´ et al., 2000; Prinjha 1998; Brosamle et al., 2000) involved the IN-1 mono-
clonal antibody (Caroni and Schwab, 1988), which iset al., 2000). The largest, Nogo-A, has a long amino-
terminal extension that possesses inhibitory activity apparently directed against an epitope in this extension
(Chen et al., 2000). A second inhibitory domain has been(Chen et al., 2000; Prinjha et al., 2000; Fournier et al.,
2001), but which has been proposed to be localized in localized to a 66 amino acid lumenal/extracellular loop
in the portion of the Nogo protein that is common to allthe cytoplasm (GrandPre´ et al., 2000), making its func-
tion in inhibition in vivo unclear—unless it is somehow three isoforms (A, B, and C) (GrandPre´ et al., 2000), and
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which is the target for a receptor protein (Nogo-66R or mice confirmed the absence of transcripts correspond-
ing to Nogo-A and -B and the maintained presence ofNgR) found on axons (Fournier et al., 2001). This portion
of Nogo is on the appropriate (i.e., lumenal or extracellu- the -C isoform (Figure 1D). Western blot analysis using
anti-Nogo antibodies demonstrated the absence oflar) side of the membrane to be involved in inhibition. It
is unclear, however, how much of the inhibitory actions Nogo-A and Nogo-B proteins in the mutant brain (Figure
1E). Similarly, immunostaining of transverse sectionsof myelin is contributed by this domain, since antibodies
against the long amino-terminal domain of Nogo-A were from adult spinal cord using the anti-Nogo-A antibody
confirmed the absence of Nogo-A in the mutant (seefound to block completely the inhibitory action of myelin
fractions containing Nogo-A in a sensory neurite out- Supplemental Figure S1 at http://www.neuron.org/cgi/
content/full/38/2/213/DC1).growth assay (Chen et al., 2000). A possible role for this
domain in inhibition in vivo is consistent with the finding
that a peptide that interferes with the interaction of Generation of Nogo-A/B/C Mutant Mice
Nogo-A and Nogo-66R can promote axonal regenera- We also generated a more severe allele of nogo by
tion in the injured adult spinal cord when administered targeting the C-terminal common region in order to dis-
in vivo (GrandPre´ et al., 2002). However, this result does rupt the transcripts of all three Nogo isoforms. We de-
not conclusively implicate the 66 amino acid loop, since signed a gene targeting scheme to replace the first of
NgR has recently been found also to be a receptor for the six common exons at the C-terminal region with
both MAG (Liu et al., 2002; Domeniconi et al., 2002) and a loxP site-flanked (floxed) neomycin resistance gene
another recently identified inhibitory protein in myelin, (Figure 1F). This exon was chosen for deletion because,
oligodendrocyte-myelin glycoprotein (OMgp) (Wang et should splicing over the selection cassette occur, a shift
al., 2002). Thus, the peptide may have produced some of open reading frame would preclude the translation of
of its effects by interfering with those ligands—or with all downstream exons and might, in addition, destabilize
other as yet unidentified inhibitory ligands for the recep- the transcripts. The targeted allele was obtained in
tor—rather than Nogo itself. AB2.2 ES cells (Figure 1G). Chimeric mice were gener-
To clarify the role of Nogo in inhibition of axon regener- ated and bred to C57BL/6 females. Three independently
ation in vivo and the domains important for inhibition, targeted ES cell clones gave germline transmission. In-
we generated mice that either lack Nogo-A and -B (but tercrosses between heterozygous mutants gave rise to
not -C) or that carry a C-terminal mutation that disrupts 49 wild-type, 90 heterozygous, and only 1 homozygous
all three isoforms, and we assessed the regenerative pup, indicating embryonic lethality of most homozygous
response of CNS axons to spinal cord injuries. Our re- mutants. This lethality does not appear to be caused by
sults reveal no evidence for enhanced regeneration in the neomycin resistance gene, including its PGK pro-
these animals. moter, since excision of this marker gene with a Cre
deleter mouse (Lewandoski et al., 1997) failed to rescue
the lethality (10 /, 31 /m, and 0 m/m out of 6 littersResults
from intercrosses between heterozygotes). We did not
determine the age at which lethality occurs, but assumeGeneration of Nogo-A/B Mutant Mice
Figure 1A shows the structure of the nogo gene, as- it is before embryonic day 9.5 (E9.5), since no homozy-
gous mutants were recovered at that stage (16 embryossessed by characterizing genomic clones isolated from
a mouse 129S5 genomic library and through analysis scored from 2 litters).
Because the Nogo-A/B mutant was viable, these re-of genomic sequence from databases. The nogo gene
spans over 50 kB and contains an A/B-specific exon sults initially suggested that the C-isoform is required
for viability. However, the single viable homozygous(exon 1), two A-specific exons, one C-specific exon, and
six A/B/C common exons. Nogo-A/B/C mutant we obtained (the escaper, see
above) proved fertile, and from it we were able to deriveTo address the role of the long amino-terminal exten-
sion of Nogo, we generated a Nogo N-terminal mutation a line of mice in which homozygosing the mutation no
longer resulted in lethality (see Experimental Proceduresin which the A and B isoforms are specifically mutated,
and only the C isoform remains. This mutation deletes an for details). In fact, the homozygous mutants were fertile
and could be maintained as a line. Southern blot analysisamino-terminal genomic fragment including the entire
coding region of exon 1 downstream of the ATG start of these animals showed that the gene targeting event
in the original ES cell line was apparently unaffectedcodon (Figure 1B) and is expected to completely abolish
Nogo-A and Nogo-B expression. The targeted allele was (data not shown). Northern analysis did not detect any
Nogo-A or -B isoform transcripts, presumably reflectingobtained in AB2.2 ES cells (derived from strain 129S7)
(Figure 1C), which was then used to generate chimeric their destabilization (Figure 1H). A lower level of a nogo
transcript that is slightly smaller than the wild-typemice. Heterozygous mutants were obtained by breeding
chimeric mice to C57BL/6 females, and the mutation nogo-C transcript was observed, which is as predicted
for the mutated nogo-C transcript (also destabilized butwas backcrossed to C57BL/6 one more time before be-
ing homozygosed. In intercrosses between (C57BL/6  still present) and is expected to produce no functional
protein. Indeed, RT-PCR and sequence analysis con-129S7) N2 heterozygotes, wild-type, heterozygous, and
homozygous progeny appeared in Mendelian ratios firmed that this transcript results from splicing over the
neomycin cassette and, if translated, will produce a(10 /, 22 /m, and 10 m/m out of 5 litters). Homozy-
gous mutants were viable, fertile, and morphologically short peptide with the first 11 amino acid residues identi-
cal to those in wild-type Nogo-C but with the next 25indistinguishable from their wild-type littermates. North-
ern blot analysis of brain tissue from adult homozygous residues translated in a shifted frame (Figure 1I and
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data not shown); importantly, the 66 amino acids in the
lumenal/extracellular loop will be absent. Western analy-
sis of whole brain extract using the anti-Nogo-A anti-
body demonstrated the absence of the A isoform (Figure
1J), as did immunostaining with the same antibody in
the adult spinal cord (data not shown). We therefore
conclude that the Nogo-A/B/C mutant likely represents
a null mutant for Nogo-C and a null or severe hypomorph
for Nogo-A and -B. The serendipitous derivation of this
viable Nogo C-terminal mutant allowed us to assess
whether regeneration is enhanced in the absence not
just of the A and B isoforms but also of Nogo-C.
It is not immediately clear how an escaper line could
arise from the otherwise lethal Nogo C-terminal muta-
tion. An insight was, however, obtained when we gener-
ated two more nogo mutant alleles (B.Z., M.T.-L., unpub-
lished observations). First, we obtained a doubly
targeted allele in which both the N-terminal and the
C-terminal region of nogo were targeted in cis (i.e., the
two targeted events occurred on the same chromo-
some). Surprisingly, this line of mice (Nogo N/C-terminal
doubly targeted allele) was homozygous viable and fer-
tile, indicating that the targeting event at the N terminus
of nogo rescues the lethality associated with the C-ter-
minal mutation. Second, we generated a nogo deletion
allele, with the genomic region between the A,B-specific
exon and the first common exon deleted by Cre-medi-
ated excision of the doubly targeted line. This allele is
expected to be completely devoid of any known Nogo
isoforms and almost certainly represents a clean null
allele. It also proved viable and fertile (see Supplemental
Table S1 at http://www.neuron.org/cgi/content/full/38/
2/213/DC1). These results argue against an essential
Figure 2. In Vitro Characterization of Myelin Obtained from Nogo-
function of Nogo-C in development, which had been A/B-Deficient Mice
originally suggested by the lethality of the Nogo C-ter-
Mouse P7 cerebellar neurons were dissociated and plated on PDL,
minal mutation. Instead, these results suggest that the wild-type myelin, and Nogo-A/B mutant myelin taken from adult
original C-terminal mutation might have caused misreg- spinal cords. Neurons were detected with an anti-tubulin antibody
ulation of an unknown transcript at or near the nogo (Tuj-1).
(A–D) Representative images of neurite growth under the followinglocus, which was subsequently reversed by the N-ter-
conditions: poly-D-lysine substrate (A), wild-type myelin substrateminal mutation (and spontaneously in the viable C-ter-
(B), substrate of myelin from Nogo-A/B-deficient mice (C), and wild-minal mutant escaper). Whatever the explanation, our
type myelin substrate with 10 M Y27632 (Rho kinase inhibitor)deletion mutant demonstrates clearly that the nogo gene added to the culture medium (D).
is not required for viability. (E) Quantification of neurite outgrowth from one representative ex-
periment out of three experiments that gave similar results. Error
bars indicate SEM.Inhibitory Activity of Nogo-A/B-Deficient Myelin
To assess whether Nogo-deficient myelin still inhibits
neurite outgrowth, we performed in vitro neurite out-
Lack of Enhanced Regenerationgrowth assays with mouse postnatal day 7 cerebellar
in Nogo-A/B Mutantsneurons. Myelin made from adult spinal cords of wild-
In vivo delivery of antibodies against Nogo-A in adulttype and Nogo-A/B mutant mice was used as a substrate
rats that were subjected to a spinal cord injury resultedfor neurite outgrowth. As shown in Figure 2, postnatal
in enhanced regeneration and sprouting of descendingcerebellar neurons grow extensive neurites on control
corticospinal tract (CST) axons (Schnell and Schwab,wells, whereas neurite outgrow is significantly inhibited
1990; Bregman et al., 1995; Brosamle et al., 2000) buton wild-type CNS myelin. CNS myelin from Nogo-A/B
no enhanced regeneration of ascending sensory axonsmutant mice is still inhibitory, but the degree of inhibition
(Oudega et al., 2000). We therefore concentrated onis less than that observed with myelin from wild-type
regeneration of CST axons. In total, we examined andmice; about a quarter of the inhibition was lost (as mea-
compared the regenerative response of 15 wild-type, 3sured by the length of neurites) (Figure 2E) (p  0.01,
heterozygous, and 21 homozygous mutant animals afterStudent’s t test). As a positive control, an inhibitor of
spinal cord injury. In all animals, a lesion of the dorsalRho-associated kinase (Y27632) also partially reversed
portion of the spinal cord (dorsal hemisection) was per-the inhibitory activity of central myelin (Figure 2E, p 
formed at thoracic level T7-8 in adult female mice. Le-0.01) (Dergham et al., 2002). These results indicate that
sions were performed with two methods: (1) using mi-Nogo-A/B contributes to the inhibitory activity of central
myelin on neurite outgrowth in vitro. croscissors followed by a microknife, or (2) using a 30
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gauge needle to puncture the dura, followed by a mi-
croknife. These lesions resulted in the transection of the
main corticospinal tracts (located in the ventral portion
of the dorsal columns), as well as the lateral corticospi-
nal tracts (sparse fibers located dorso-laterally within
the white matter surrounding the spinal cord). To visual-
ize the descending corticospinal tract axons, the tracer
biotinylated dextran amine (BDA) was injected into the
sensorimotor cortex at the time of the injury. In the first
cohort of animals studied (five wild-type, three heterozy-
gous, and eight homozygous mutants), BDA was in-
jected into the cortex bilaterally. In subsequent experi-
ments, injections were performed unilaterally to help
examine whether regenerative sprouting occurred across
the midline. To assess axonal regeneration, animals
were sacrificed 14–19 days after injury for histological
analysis, to maximize chances for detecting early stages
of regeneration. Spinal cord segments either 1 or 2.5
cm long, with the lesion site approximately in the center,
were sectioned in the sagittal plane (25 m sections). All
sections were collected in serial order so that individual
labeled axons could be traced from section to section,
allowing reconstruction of the axonal projections. In ani-
mals where only a 1 cm block was taken, additional 3
mm blocks 0.5 cm rostral and 0.5 cm caudal to the 1
cm block were sectioned in the transverse plane.
There was no systematic difference between mutant
and control animals in the appearance of the lesions,
although the extent varied somewhat from animal to
animal. In most, lesions were as designed (i.e., they
completely transected the dorsal half of the spinal cord
and extended beyond the central canal, and so strictly
speaking should be characterized as “dorsal over-hemi-
sections”). Macrophages accumulated in the lesion site
to a variable extent, as assessed in tissue sections (data
not shown). In many animals, a dense network of pre-
sumed fibroblastic tissue was noted at the lesion site
(e.g., Figures 3A and 3B).
There was no indication of a greater degree of regen-
eration or sprouting in the Nogo-A/B mutant animals.
Indeed, we did not detect any difference in the distribu-
tion of labeled CST axons between mutants and con-
trols. Thus, the following description applies to both, as Figure 3. Absence of Enhanced Regeneration of Corticospinal Fi-
well as to the few heterozygotes that were analyzed. bers in Nogo-A/B Mutant after Dorsal Hemisection Injury
(We excluded from this analysis four animals, discussed (A–D) The labeled CST axons around the lesion site in representative
below, in which some sparing of main CST axon fibers controls (A and C) and Nogo-A/B mutants (B and D) 14–19 days
after dorsal hemisection injuries. Arrows indicate the approximateor unusual labeling was observed).
location of the lesion site. In (A) and (B), arrowheads point to scarIn all animals, labeled CST axons could be seen in
tissue at the lesion site. In (C) and (D), the lesion site is to the righttheir normal location in the ventral part of the dorsal
and outside of the area shown. Scale bar equals 250 m.funiculus rostral to the lesion, although the extent of
(E–H) High-magnification images of boxed areas in (C) and (D). (E)
labeling varied between animals. Sample cases exhib- and (F) illustrate the axon endings and the collateral branches near
iting substantial labeling are illustrated (Figures 3A–3D). the injury site. Asterisks mark stained red blood cells. (G) and (H)
In most cases, labeled CST axons could be followed to show the end of the main CST where characteristic retraction bulbs
(some indicated by white arrowheads) can be seen. Scale bar equalswithin 100–250 m of the edge of the lesion, where
62.5 m in (E)–(H).they ended abruptly in a dense cluster of characteristic
(I) Quantification of the extent of regeneration in Nogo-A/B mutantsretraction bulbs (e.g., Figures 3G and 3H). When the
and wild-type controls. x axis indicates specific locations along thetermination of the main bundle of CST axons was visual-
rostrocaudal axis of the cord; y axis (axon index) indicates the ratio
ized at high magnification, multiple branches could be of the average number of axons counted outside the main CST at
seen that extended down into the underlying gray matter each rostrocaudal location to the numbers of fibers labeled in the
toward the lesion site, often taking a meandering course medulla (mean  SEM). L, lesion site; Mid, halfway between end of
main CST and the lesion site. No statistically significant difference(Figures 3E and 3F). However, these axons for the most
between numbers of sprouting or regenerating axons at any levelpart ended just prior to the approximate site of injury.
along the rostrocaudal axis was observed between mutants andTheir appearance was suggestive of abortive regenera-
wild-type animals.tion. These fine labeled axons were seen in both Nogo-
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A/B mutant and control animals (Figures 3E and 3F). In (mutants and controls) was an abrupt end to labeled
axons at the lesion site except for the fine branches thata few animals of each genotype, one to three axons
were observed in the distal segment below the injury projected from the distal portion of the main CST into
the adjacent gray matter. Axons in the gray matter likelysite; the number and distribution was similar in mutants
and controls (Figure 3I). represent mostly normal collateral branches to that seg-
ment, although we cannot exclude that some are regen-To assess whether subtle differences might be pres-
ent, quantification of fibers in a subset of animals was erative sprouts. In any case, there was no systematic
difference between Nogo-A/B mutant and control ani-undertaken. These animals were selected in a blinded
manner for quantification based on the following criteria: mals in the extent of these collaterals.
This description excluded four animals. In three of(1) staining was of uniform high quality, (2) all sagittal
sections were recovered, (3) no obviously spared main them, two wild-type and one mutant, a large cohort of
labeled axons could be seen in the dorsal funiculusCST axons were observed, (4) the lesion site could be
defined, and (5) medullary sections of high quality were caudal to the lesion. These axons almost certainly were
spared by the lesion, probably by being pushed asideobtained for normalization of tracing. Seven wild-type
and eight mutant animals satisfied these criteria. The as it was made, based on their length (several millimeters
below the lesion), appearance (straight and unbranched),quantification method is described in Experimental Pro-
cedures. Briefly, the numbers of fibers running outside and location (in the normal position of the tract). In the
fourth animal, a wild-type, we were surprised to observethe main dorsomedial CST at different rostrocaudal lev-
els from the lesion site were analyzed using a light micro- what at first appeared to be a population of labeled
axons diffusely distributed in the lateral column ipsilat-scope. In each animal, labeled axons were counted at
multiple designated rostrocaudal levels in the sagittal eral to the main labeled tract, in transverse sections
rostral and caudal to the lesion site (see Supplementalsections running through the main CST and sections
adjacent to it. To correct for interanimal tracing variabil- Figure S2A at http://www.neuron.org/cgi/content/full/
38/2/213/DC1) as well as in the sagittal sections throughity, the numbers of counted axons in each animal were
normalized to the numbers of BDA-positive CST fibers the lesion site (data not shown). Closer inspection re-
vealed unusual features of these profiles: when the sec-in the medullary pyramid rostral to the pyramidal decus-
sation. Quantification was performed in a blinded man- tions were viewed using dark field illumination, all other
labeled axons reflected light but these profiles did notner. There was no significant difference between mu-
tants and wild-type animals in the numbers of fibers at (Supplemental Figures S2B and S2C), and at high magni-
fication they appeared thicker and had a “hollow” ap-any level (Figure 3I).
Transverse sections rostral and caudal to the lesion pearance (data not shown) distinct from the thin labeled
fibers seen elsewhere. The nature of these stained pro-site were also analyzed in the 10 wild-type and 13 mutant
animals that received unilateral tracer injections (Figure files has not been established, so this animal was also
excluded.4). Labeled CST axons were evident in their normal loca-
tion in the ventral portion of the dorsal columns (open During the postsurgical survival period, we assessed
the degree of behavioral impairment in a cohort of homo-arrows in Figures 4A–4H) and, in most cases, between
a few and dozens of labeled axons could also be seen zygous mutant and wild-type animals using the BBB
assessment scale, which evaluates open field locomotorin the dorsal portion of the lateral column (the normal
location of the lateral CST, e.g., thin arrows in Figures behavior (Basso et al., 1995). All the animals recovered
locomoter ability to some extent over the 2 week period4F and 4H). Many collaterals extended from the main
tracts ventrally into the gray matter (Figures 4B, 4D, 4F, (see Supplemental Figure S3A at http://www.neuron.
org/cgi/content/full/38/2/213/DC1), but there was noand 4H). In many animals, a number of labeled axons
crossed the midline to enter the gray matter on the side statistically significant difference between the mutants
and wild-type animals in the degree of functional re-contralateral to the labeled main tract (that is, ipsilateral
to the injection; see especially Figures 4J and 4L). In covery.
The absence of regeneration in these animals con-some animals, there were also a few labeled axons in
the dorsal column on the side ipsilateral to the injection trasts with the apparently extensive regeneration ob-
served by Dr. S. Strittmatter and colleagues in a different(e.g., arrowheads in Figures 4F and 4H). Although there
was animal to animal variability, there was no systematic Nogo mutant mouse line (personal communication; see
Discussion). We were concerned that the difference indifference between Nogo-A/B mutant and control mice.
While there was heavy labeling of the CST above the these two studies could reflect a difference in the
method of producing the lesion. To address this directly,level of the injury (Figures 4A–4H), we did not detect any
labeled fibers below the level of the injury in transverse Dr. S. Strittmatter generously offered to have lesions
performed on our mice by a member of his laboratory,sections in almost all Nogo-A/B mutant and control ani-
mals (e.g., Figures 4I and 4K). In one Nogo-A/B mutant Dr. S. Li, who also performed all of the lesions in their
study. Lesions were performed following the exact pro-and one control animal, we did observe a small number
(1–3) of fibers in the transverse sections below the level tocol used in analysis of their mice (for details, see their
paper [Kim et al., 2003] in this issue of Neuron). Histologi-of the lesion; both animals were ones in which a small
number of fibers had been observed caudal to the lesion cal analysis was performed by Dr. S. Li and Dr. B. Zheng
on the six mutant and four wild-type animals that suc-in sagittal sections (Figure 5). Thus, although hundreds
of labeled axons entered the segment just rostral to the cessfully survived the procedure. This analysis failed
to detect any evidence of enhanced regeneration orinjury (too many to accurately count), almost none could
be detected caudal to the injury site. sprouting above or below the lesion in our mouse line
(data not shown), thus indicating that the differing re-Thus, the characteristic picture seen in all animals
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Figure 4. Distribution of Corticospinal Fibers on Transverse Sections in Segments Rostral and Caudal to the Injury in Nogo-A/B Mutant and
Control Mice
(A), (C), (E), (G), (I), and (K) are transverse sections of the spinal cord taken from about 0.5 cm rostral (A, C, E, and G) or 0.5 cm caudal (I and
K) to the injury site of representative wild-type (A, E, and I) and Nogo-A/B mutant (C, G, and K) mice, which received unilateral tracer injection.
Animals shown in (A) and (C) correspond to those shown in Figures 3C and 3D, respectively. (E) and (I) are from the same wild-type animal;
(G) and (K) are from the same mutant animal. Scale bar equals 300 m.
(B), (D), (F), (H), (J), and (L) are high-magnification images of the boxed areas in (A), (C), (E), and (G). Open arrows in (A)–(H) indicate the labeled
main CST (in the ventral part of the dorsal column on the left hand side). (B), (D), (F), and (H) show the heavily labeled main CST (open arrows)
and many labeled collaterals distributed throughout the gray matter. In (F) and (H), thin arrows indicate the small population of labeled axons
in the dorsal part of the lateral column at the normal location of the lateral CST; black arrowheads indicate the few main CST axons labeled
ispilateral to the injection site. (J) and (L) show some labeled axons in the gray matter contralateral to the labeled main CST. Note that there
are hundreds of labeled axons evident in the rostral segments (E and G), whereas no labeled axons are detectable in the caudal segments
(I and K). Scale bar equals 60 m.
sults between the two laboratories likely reflect differ- Assessment of locomotor function using the BBB rat-
ences between mouse lines rather than differences in ing scale revealed that Nogo-A/B/C mutant animals on
surgical protocols. average exhibited slightly better locomotor function (es-
pecially at the first two time points), but the difference
between groups was not statistically significant at anyLack of Enhanced Regeneration
time point (see Supplemental Figure S3B at http://in Nogo-A/B/C Mutants
www.neuron.org/cgi/content/full/38/2/213/DC1). As-The C isoform of Nogo is also expressed in the central
sessment of the distribution of the CST in Nogo-A/B/Cnervous system (Huber et al., 2002), raising the question
mutants again revealed no differences between mutantswhether removal of that isoform, along with the A/B
and controls. The CST ended abruptly just rostral to theisoforms, could cause greater regeneration than that
lesion site in characteristic retraction bulbs (Figures 5Aseen in our Nogo-A/B mutant animals. We performed
and 5B). A few axon collaterals could be seen just rostralspinal cord lesions in Nogo-A/B/C mutant mice obtained
to the terminal end bulbs, and these extended downfrom breeding the one initial escaper, and we examined
into the underlying gray matter (Figures 5A and 5B).the corticospinal projection for regeneration. For this
Evaluation of transverse sections from mutant andexperiment, animals were allowed to survive for longer
control animals revealed heavy labeling of the CSTperiods following the spinal cord injury (9 weeks) in case
above the level of the injury; again, hundreds of labeledthe failure to detect regeneration was due to the short
axons entered the segment rostral to the injury (for ex-postinjury survival period. Thus, animals received bilat-
amples, see Figures 5C and 5D). At the same time, ineral BDA injections 7 weeks after the spinal cord injury
all animals but one there were no labeled axons below(and 2 weeks prior to being sacrificed). Eight wild-type
the level of the injury (Figures 5E and 5F). In the oneand eight mutant animals that survived the procedure
were analyzed. exceptional case (Figure 5F), which was a mutant, we
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Figure 5. Distribution of Corticospinal Fibers
in Injured Nogo-A/B/C Mutant and Control
Mice
The photomicrographs illustrate the distribu-
tion of labeled CST axons in representative
control and Nogo-A/B/C mutant animals,
which received bilateral tracer injection. Ge-
notypes are indicated on the top. (A) and (B)
illustrate representative sagittal sections just
rostral to the injury site; (C) and (D) illustrate
transverse sections taken approximately 0.5
cm rostral to the injury. (E) and (F) illustrate
sections taken approximately 0.5 cm caudal
to the injury. Note that there are hundreds of
labeled axons evident in the rostral seg-
ments, whereas only one labeled axon was
detected in the caudal sections taken from
any of the cases. This single example of a
labeled axon caudal to the injury is illustrated
in the high-magnification inset in (F).
did detect a single labeled axon in the caudal segment confirming that Nogo-A/B contributes to inhibition in
vitro—our results imply that loss of Nogo-A/B is not(see high-magnification inset in Figure 5F). We were not
able to trace this axon through more rostral segments, sufficient to permit significant regeneration in vivo, pre-
sumably either because Nogo’s in vitro activity does notand so we were unable to define its course to determine
whether it was spared or had regenerated. reflect a physiological role for Nogo in blocking regener-
ation in vivo, or because other inhibitors are sufficient
to block regeneration.Discussion
What accounts for the difference between our studies
and the antibody perturbation experiments? In thoseNogo has been implicated in regenerative failure in the
central nervous system through antibody perturbation studies, the IN-1 monoclonal antibody was initially deliv-
ered through implantation of the IN-1 hybridoma cellstudies (Schnell and Schwab, 1990; Bregman et al.,
1995; Thallmair et al., 1998; Brosamle et al., 2000). We line into the cortex in rats and led to regeneration of a
small number of fibers past the lesion site following ahave generated mutant mice that lack Nogo-A/B or
-A/B/C expression, but we did not detect an enhance- bilateral CST lesion (Schnell and Schwab, 1990), as well
as to increased compensatory sprouting of unlesionedment of regeneration of corticospinal tract axons follow-
ing the same type of dorsal column lesion that was axons following a unilateral CST lesion (Thallmair et al.,
1998). Subsequently, large amounts of IN-1 Fab frag-used in the antibody delivery experiments. In fact, any
evidence of minimal regeneration, including apparent ments were directly infused into the injury site and stimu-
lated regeneration past the lesion in about 60% of ratscollateral sprouting rostral to the lesion, and occasional
axons below the lesion site in some animals, was seen in short term (2 week) dorsal hemisection studies (Bro-
samle et al., 2000). Although striking, these studies arein both mutant and wild-type animals. Quantification
also failed to detect any statistically significant differ- limited by the fact that IN-1 is not specific for Nogo and
reacts with multiple molecular species (Spillmann et al.,ence in the number of labeled fibers between wild-type
and mutant animals at various rostral-caudal levels rela- 1998), making its target uncertain. More specific anti-
bodies have been made (Chen et al., 2000), but their intive to the lesion site. Although we found that the ab-
sence of Nogo-A/B in these animals reduced the amount vivo effects have not yet been reported. In addition, it is
not understood at present why evidence of regenerationof inhibitory activity of myelin substrates tested in vitro—
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was found in only a subset of animals, and why IN-1 of axons not labeled in our studies, (2) require some
specific type of lesion different from the one we or Dr.failed to stimulate regeneration of lesioned sensory ax-
ons in the dorsal columns (Oudega et al., 2000), despite Strittmatter’s laboratory performed, or (3) require a par-
ticular genetic background different from the one wethe fact that IN-1 dramatically improves sensory axon
growth on myelin in vitro (e.g., Chen et al., 2000). used. If highly restrictive conditions like these are re-
quired for a successful regenerative response, then theIn our studies, similar techniques were used to pro-
duce CST lesions and to trace CST axons, yet animals relevance to regeneration following traumatic injury to
the spinal cord might be limited.lacking Nogo-A/B did not exhibit any evidence of en-
hanced regeneration 14–19 days after a lesion. We also A similar discrepancy is also apparent in the different
results obtained in studies of mice with different muta-did not observe any evidence of enhanced sprouting of
CST axons above the lesion site (e.g., enhanced contra- tions of the nogo gene reported by two other groups in
companion papers in this issue of Neuron (Kim et al.,lateral projections) in the mutants compared to the con-
trols. The absence of either regeneration or sprouting 2003; Simonen et al., 2003). In both studies, the large
Nogo-A-specific exon was disrupted (although differentis in line with the lack of improvement in the BBB behav-
ioral score in mutant animals compared to controls. effects were observed on expression of the Nogo-B
isoform).There are two possible explanations for the discrep-
ancy between our results and those obtained in the First, Dr. S. Strittmatter and colleagues (Kim et al.,
2003) have analyzed a mutant mouse in which the largeantibody perturbation experiments.
First, it is possible that in the antibody perturbation Nogo-A-specific exon is disrupted as a result of a gene
trap insertion; while the trapping vector was insertedexperiments, regeneration was stimulated not by inhibi-
tion of Nogo, but by IN-1 interfering with one of the into a Nogo-A-specific exon, the consequences of this
insertion for Nogo expression (assessed by Northerndistinct molecular species detected by the IN-1 antibody
(Spillmann et al., 1998). In this scenario, Nogo-A/B does and Western analyses) are apparently similar to our
Nogo-A/B mutant. Specifically, both Nogo-A and -B ex-not contribute significantly to regeneration block in the
normal adult nervous system. pression appear to be disrupted (Nogo-C expression is
apparently unchanged). After a lesion, they observedSecond, IN-1 may have produced its effects by in-
terfering with Nogo function. If so, our failure to detect extensive sprouting and regeneration that are most pro-
nounced on the side contralateral to the labeled cortico-regeneration in our Nogo knockout mice could be ex-
plained by one or more of the following possibilities. (1) spinal tract, although it is uncertain whether this is true
in adult animals or only in young ones (personal commu-It is possible that only a subpopulation of CST axons
regenerated, and that we failed to label that population. nication).
It is difficult to account for the remarkable divergenceThis seems unlikely, given the extent of labeling in our
studies. (2) The specific surgical paradigm we used may between our study and theirs. We studied both young
and old animals (the median age was young [8 weeks]),have made regeneration more difficult. This again seems
unlikely, since the techniques used were similar (if not but we saw no regeneration or enhanced sprouting. We
do not believe that differences in surgical or labelingidentical) and since no regeneration was observed in
our Nogo-A/B mutants when they were lesioned by Dr. techniques can explain the difference, since similar
techniques were used by both groups and since Dr.S. Li using a protocol that apparently allowed regenera-
tion in a line of mice analyzed by him in Dr. Strittmatter’s Strittmatter reports extensive sprouting far rostral to the
lesion, which should be insensitive to the precise lesionlaboratory. (3) Our studies were performed in mice,
whereas the antibody treatment studies were performed techniques that are used.
We are thus left with three possible explanations forin rats. It is conceivable that more regeneration could be
observed in a different species or in a different genetic the discrepancy. The first is differences in genetic back-
grounds; however, if this is the explanation, it againbackground (ours was mixed, about three-quarters
C57BL/6 and one-quarter 129S7). (4) The antibody treat- calls into question the robustness of regeneration that
is possible following loss of Nogo function. The secondment was acute, whereas our genetic deletion was pres-
ent through development. It is conceivable that compen- is that in our mutant, but not Dr. Strittmatter’s, some
compensatory change occurred that suppressed regen-satory changes occurred in the mutant mice that
diminished regenerative capacity. (5) We also consid- eration. The third is that Dr. Strittmatter’s phenotype
reflects more than a loss of Nogo function. The mutationered the possibility that the absence of a regenerative
response in Nogo-A/B mutants might be due to the they analyzed was generated by Lexicon Genetics by
random insertion of a complex gene trap vector con-presence of the Nogo-C isoform (although the antibody
targeted Nogo-A specifically). We therefore generated taining a strong promoter (Zambrowicz et al., 1998),
and it is possible that this has resulted in alterationmice in which all three isoforms are mutated through
targeting of the C-terminal common region. Although or deregulation of other neighboring genetic loci, with
regeneration being caused secondarily by this change.we initially found that these mutants are embryonic le-
thal, we did obtain one viable homozygous mouse from Second, Dr. M. Schwab and colleagues (Simonen et
al., 2003) generated a distinct mutant in which the samewhich we were able to derive a line of mice that appar-
ently lack Nogo-A, -B, and -C. However, no evidence of large Nogo-A-specific exon was disrupted by conven-
tional gene targeting. This results in loss of Nogo-A butenhanced regeneration or sprouting in these animals
was observed either. also a dramatic upregulation in Nogo-B expression in
spite of the fact that this mutation disrupts the sameThus, if a regenerative response of CST axons is pos-
sible in the absence of Nogo-A, -B, and -C in mice, our exon as that trapped in the mutant analyzed by Dr.
Strittmatter and colleagues. In this mutant, very limitedresults imply that this may (1) involve a subpopulation
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adulthood. While most of our intercrosses were between (C57BL/6though consistent regeneration was observed, but with-
129S7) F1 heterozygotes, this escaper arose from a (F1  chimera)out the lateralized effect observed by Dr. Strittmatter
mating. Mating of this homozygous escaper to heterozygous fe-(personal communication). While this result is consistent
males gave rise to heterozygous and homozygous progeny in a ratio
with Nogo-A contributing to regeneration failure, it that deviates from 1:1 (45/m and 14 m/m), indicating the continued
would seem to imply a modest role for Nogo-A alone. presence of some inviable homozygous progeny. Five heterozygous
progeny that derived from the escaper were expanded clonally (eachAs well, it is conceivable that the phenotype reflects
presumably carrying one of the two mutant alleles from the escaper),a gain-of-function phenotype from deregulation of
three of which, when intercrossed, readily gave rise to viable andNogo-B expression.
fertile homozygotes, while the other two continued to produce invia-Thus, future studies are required to determine whether
ble homozygous progeny.
the differences between our results and those of the We subsequently targeted the nogo N terminus through a second
other two groups reflect some limitation of our models, gene targeting event in an ES cell line that already carried the tar-
geted C-terminal mutation that had proved to be homozygous lethalor instead reflect the fact that something more than loss
in mice (this particular ES cell line was different from the one fromof Nogo-A and/or -B is occurring in their models. The
which the escaper derived). This resulted in an ES cell line thatpossibility of complex genetic interactions following dis-
carries both Nogo N- and C-terminal mutations on the same chromo-ruption of the nogo locus is highlighted by the opposite
some (the doubly targeted allele). Upon transmission through the
effects on Nogo-B expression of the two mutations ana- germline, homozygous doubly targeted Nogo mutants were readily
lyzed by the other two groups (even though the same obtained from intercrosses between heterozygotes. A full nogo dele-
tion allele was generated by breeding the doubly targeted allele toexon was disrupted in both), and by the complexity in
a Cre deleter line (Lewandoski et al., 1997) and was also viable.the pattern of lethality in our four Nogo mutants (with a
C-terminal mutation initially causing lethality that was
Western Blot and Immunocytochemistryreversed both spontaneously and by a second N-ter-
A peptide specific to the A isoform of mouse Nogo, SYDGIKLEPENPminal mutation; see Supplemental Table S1 at http://
PPYEEA, was used to generate rabbit anti-Nogo-A polyclonal anti-
www.neuron.org/cgi/content/full/38/2/213/DC1). bodies. This peptide corresponded to that used previously to gener-
Whatever the explanation for the different degrees of ate an antibody to rat Nogo-A (Chen et al., 2000), with one amino acid
regeneration observed in the three studies, our results difference. Antiserum was affinity purified with the same peptide
and used for Western blot analysis (1:500 dilution), using an HRP-nonetheless demonstrate that removal of Nogo-A and
conjugated goat anti-rabbit secondary antibody. Both antiserum-B, or of all three isoforms, is not sufficient to allow
and purified antibody were used for immunohistochemistry at aextensive regeneration or sprouting of corticospinal
1:300 dilution, using a FITC-conjugated goat anti-rabbit secondary
tract axons following injury, and thus raise questions antibody. Nogo-B was detected with a commercial antibody di-
as to the normal contribution of Nogo to regeneration rected against the N terminus of Nogo-A/B (Santa Cruz).
failure. Future studies will determine whether a greater
regenerative response in our animals can be observed Neurite Outgrowth Assay
Myelin was prepared from mouse spinal cords as described (Colmanunder other circumstances, in particular whether re-
et al., 1982). Eight-well chamber slides were precoated with poly-moval of other inhibitors like MAG or OMgp in addition
D-lysine, coated with myelin (1 mg total protein per well), and driedto Nogo results in an enhanced regenerative response.
overnight, then exposed to laminin (3 g/ml) for 2 hr. Mouse P7
cerebellar cells were prepared as described (Wang et al., 2002),
plated at a density of 5  104 cells/well, incubated for 22 hr, thenExperimental Procedures
fixed and stained with an anti-tubulin antibody (TuJ1, Covance).
Neurite lengths were measured from a total of about 400–500 neu-Gene Targeting at the nogo Locus
rons on six representative images taken per well; 3 wells per con-Two overlapping clones covering the N-terminal exon and four over-
dition.lapping clones covering the C-terminal common exons of nogo were
isolated from a mouse 129S5 (coisogenic to 129S7) genomic library.
To target the N terminus to generate Nogo-A/B mutants, a replace- Surgery and Care of Animals
All Nogo-A/B mutants and their controls that were analyzed werement vector was constructed with an Frt-flanked PGK-Hprt minigene
as the positive selection marker and HSVTK as the negative selec- in a (C57BL/6  129S7) N2 background. All Nogo-A/B, Nogo-A/B/C
mutants, and their controls that were analyzed were in a (C57BL/6tion marker. A fusion reporter gene IRES-GFPLacZ and a loxP site
were also included in the targeting vector. A 1 kb genomic fragment 129S7) NE2 background. Female mice 6 to 14 weeks old (most
were 6 to 10 weeks old), age-matched between genotypes, werebetween the NcoI site in exon 1 and the first BamHI site in intron 1
was deleted. The targeting vector was electroporated into AB2.2 anesthetized with Avertin (1.3% tribromoethanol and 0.8% amyl
alcohol; Sigma-Aldrich, St. Louis, MO). The hair on the back wasES cells. A 0.6 kb 5 external probe was used to detect targeted ES
cell clones. From 90 ES cell clones screened by Southern blot, 53 shaved and swabbed with Betadine. A midline incision was made
over the thoracic vertebrae, the paravertebral muscles were sepa-targeted clones were identified.
To target the Nogo C-terminal region to generate Nogo-A/B/C rated from the vertebral column and retracted, and a laminectomy
was performed at the desired level (T7-8). Dorsal hemisection injur-mutants, a replacement vector was constructed with a floxed neo-
mycin resistance gene as the positive selection marker and HSVTK ies were produced in one of two ways. For the experiments involving
Nogo-A/B/C mutants and their littermate controls, a fine microknifeas the negative selection marker. The two loxP sites in this vector
are in the same orientation as the one in the N-terminal targeting was lowered 0.7 mm into the cord near the midline to the level of
the central canal. The microknife was then drawn across the dorsalvector described above when targeted at the nogo locus, so that a
deletion can be made from a doubly targeted allele with Cre-medi- aspect of the spinal cord through the dura. The procedure was
then repeated going in the opposite direction. For the experimentsated excision. A 1.9 kb SacI-HindIII genomic fragment containing
the first common exon was deleted. A 1.5 kb 5 external probe was involving the Nogo-A/B mutant animals and their controls, the dorsal
spinal cord was first either cut with a pair of microscissors, or theused to detect targeted ES cell clones. Among 180 ES cell clones
screened by Southern blot, 12 targeted clones were identified. Het- dura was punctured with a 30 gauge needle bilaterally on the lateral
aspects of the cord; in either case, this was followed by drawing aerozygous Nogo-A/B/C mutant mice were derived from three of
these ES cell lines. As described in the text, intercrosses of these fine microknife through the dorsal spinal cord to assure complete
hemisection. After hemostasis was achieved, the muscle layers andmice generally failed to yield any viable homozygous progeny, ex-
cept for a single escaper—a homozygous male pup that grew to the skin were sutured.
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For short-term experiments, after closure of the wound, animals deleter mouse line; Z. He and K. Wang for sharing reagents and
protocols; S. McConnell for sharing surgical equipment; and F.were passed to a second surgical station where they received injec-
tions of tetramethylrhodamine and biotin-conjugated dextran, Bradke, J. Atwal, and other members of the M.T.-L. laboratory for
helpful discussions. We thank Drs. S. Strittmatter and M. Schwab10,000 MW, lysine fixable (mini-ruby, Molecular Probes) into the
sensorimotor cortex. In one set of experiments, animals received for extensive discussions on experimental procedures and for shar-
ing their unpublished data prior to publication. We thank Dr. Stritt-bilateral injections; in the second the animals received unilateral
injections. In most experiments, two injections were made per hemi- matter further for allowing the analysis of our mice in his laboratory
by his postdoctoral fellow, Dr. S. Li, and J.-E. Kim for help withsphere, delivering 0.5 l of a 10% solution of BDA at the following
coordinates: Site 1, 1.0 mm lateral, 0.5 anterior to bregma, 0.5 mm those experiments as well. We also thank Dr. Schwab and Dr. V.
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scalp was sutured. The entire operative procedure, including spinal of the Howard Hughes Medical Institute.
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